Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Metabolic and vascular features of dynamic contrast-enhanced breast magnetic resonance imaging and (15)O-water positron emission tomography blood flow in breast cancer.

Eby PR, Partridge SC, White SW, Doot RK, Dunnwald LK, Schubert EK, Kurland BF, Lehman CD, Mankoff DA.

Acad Radiol. 2008 Oct;15(10):1246-54. doi: 10.1016/j.acra.2008.03.019.

2.

Association between serial dynamic contrast-enhanced MRI and dynamic 18F-FDG PET measures in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer.

Partridge SC, Vanantwerp RK, Doot RK, Chai X, Kurland BF, Eby PR, Specht JM, Dunnwald LK, Schubert EK, Lehman CD, Mankoff DA.

J Magn Reson Imaging. 2010 Nov;32(5):1124-31. doi: 10.1002/jmri.22362.

3.

Correlation Between F-18 Fluorodeoxyglucose Positron Emission Tomography Metabolic Parameters and Dynamic Contrast-Enhanced MRI-Derived Perfusion Data in Patients with Invasive Ductal Breast Carcinoma.

Kim TH, Yoon JK, Kang DK, Lee SJ, Jung YS, Yim H, An YS.

Ann Surg Oncol. 2015 Nov;22(12):3866-72. doi: 10.1245/s10434-015-4526-z. Epub 2015 Mar 25.

PMID:
25805237
4.

Tumor metabolism and perfusion ratio assessed by 18F-FDG PET/CT and DCE-MRI in breast cancer patients: Correlation with tumor subtype and histologic prognostic factors.

An YS, Kang DK, Jung YS, Han S, Kim TH.

Eur J Radiol. 2015 Jul;84(7):1365-70. doi: 10.1016/j.ejrad.2015.03.026. Epub 2015 Mar 30.

PMID:
25886700
5.

Evaluation of neuroendocrine liver metastases: a comparison of dynamic contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography.

Armbruster M, Sourbron S, Haug A, Zech CJ, Ingrisch M, Auernhammer CJ, Nikolaou K, Paprottka PM, Rist C, Reiser MF, Sommer WH.

Invest Radiol. 2014 Jan;49(1):7-14. doi: 10.1097/RLI.0b013e3182a4eb4a.

PMID:
24002080
6.

Tumor metabolism and perfusion in head and neck squamous cell carcinoma: pretreatment multimodality imaging with 1H magnetic resonance spectroscopy, dynamic contrast-enhanced MRI, and [18F]FDG-PET.

Jansen JF, Schöder H, Lee NY, Stambuk HE, Wang Y, Fury MG, Patel SG, Pfister DG, Shah JP, Koutcher JA, Shukla-Dave A.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):299-307. doi: 10.1016/j.ijrobp.2010.11.022. Epub 2011 Jan 13.

7.

Analysis of blood flow and glucose metabolism in mammary carcinomas and normal breast: a H2(15)O PET and 18F-FDG PET study.

Hentschel M, Paulus T, Mix M, Moser E, Nitzsche EU, Brink I.

Nucl Med Commun. 2007 Oct;28(10):789-97.

PMID:
17728609
8.

Use of H2(15)O-PET and DCE-MRI to measure tumor blood flow.

de Langen AJ, van den Boogaart VE, Marcus JT, Lubberink M.

Oncologist. 2008 Jun;13(6):631-44. doi: 10.1634/theoncologist.2007-0235. Review.

9.

Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging--prospective assessment.

Tateishi U, Miyake M, Nagaoka T, Terauchi T, Kubota K, Kinoshita T, Daisaki H, Macapinlac HA.

Radiology. 2012 Apr;263(1):53-63. doi: 10.1148/radiol.12111177.

PMID:
22438441
10.

Evaluation of breast tumor blood flow with dynamic first-pass 18F-FDG PET/CT: comparison with angiogenesis markers and prognostic factors.

Cochet A, Pigeonnat S, Khoury B, Vrigneaud JM, Touzery C, Berriolo-Riedinger A, Dygai-Cochet I, Toubeau M, Humbert O, Coudert B, Fumoleau P, Arnould L, Brunotte F.

J Nucl Med. 2012 Apr;53(4):512-20. doi: 10.2967/jnumed.111.096834. Epub 2012 Feb 17.

11.

18F-FDG kinetics in locally advanced breast cancer: correlation with tumor blood flow and changes in response to neoadjuvant chemotherapy.

Tseng J, Dunnwald LK, Schubert EK, Link JM, Minoshima S, Muzi M, Mankoff DA.

J Nucl Med. 2004 Nov;45(11):1829-37.

12.

Metabolic-flow relationships in primary breast cancer: feasibility of combined PET/dynamic contrast-enhanced CT.

Groves AM, Wishart GC, Shastry M, Moyle P, Iddles S, Britton P, Gaskarth M, Warren RM, Ell PJ, Miles KA.

Eur J Nucl Med Mol Imaging. 2009 Mar;36(3):416-21. doi: 10.1007/s00259-008-0948-1. Epub 2008 Sep 26.

PMID:
18818917
13.

Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy.

Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Charlop A, Lawton TJ, Schubert EK, Tseng J, Livingston RB.

J Nucl Med. 2002 Apr;43(4):500-9.

14.

The assessment of breast cancer response to neoadjuvant chemotherapy: comparison of magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography.

Park JS, Moon WK, Lyou CY, Cho N, Kang KW, Chung JK.

Acta Radiol. 2011 Feb 1;52(1):21-8. doi: 10.1258/ar.2010.100142.

PMID:
21498321
16.

Prognostic Value of 68Ga-NOTA-RGD PET/CT for Predicting Disease-Free Survival for Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy and Surgery: A Comparison Study With Dynamic Contrast Enhanced MRI.

Kim YI, Yoon HJ, Paeng JC, Cheon GJ, Lee DS, Chung JK, Kim EE, Moon WK, Kang KW.

Clin Nucl Med. 2016 Aug;41(8):614-20. doi: 10.1097/RLU.0000000000001274.

PMID:
27276207
17.
18.

¹⁸F-FDG PET/CT imaging versus dynamic contrast-enhanced CT for staging and prognosis of inflammatory breast cancer.

Champion L, Lerebours F, Cherel P, Edeline V, Giraudet AL, Wartski M, Bellet D, Alberini JL.

Eur J Nucl Med Mol Imaging. 2013 Aug;40(8):1206-13. doi: 10.1007/s00259-013-2405-z. Epub 2013 May 3.

PMID:
23640467
19.

Diagnostic accuracy of dynamic gadoxetic-acid-enhanced MRI and PET/CT compared in patients with liver metastases from neuroendocrine neoplasms.

Armbruster M, Zech CJ, Sourbron S, Ceelen F, Auernhammer CJ, Rist C, Haug A, Singnurkar A, Reiser MF, Sommer WH.

J Magn Reson Imaging. 2014 Aug;40(2):457-66. doi: 10.1002/jmri.24363. Epub 2013 Dec 18.

PMID:
24347148
20.

US-localized diffuse optical tomography in breast cancer: comparison with pharmacokinetic parameters of DCE-MRI and with pathologic biomarkers.

Kim MJ, Su MY, Yu HJ, Chen JH, Kim EK, Moon HJ, Choi JS.

BMC Cancer. 2016 Feb 1;16:50. doi: 10.1186/s12885-016-2086-7.

Supplemental Content

Support Center